Efficiency of using fibrinolysis inhibitor to reduce intraoperative blood loss in patients with disseminated ovarian cancer after 3 cycles of neoadjuvant chemotherapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To analyze the efficiency of intraoperative injection of Ambene to reduce blood loss during surgical treatment in patients with disseminated ovarian cancer after neoadjuvant chemotherapy. Subjects and methods. The investigation enrolled 36 patients with morphologically verified disseminated ovarian cancer (Stages III-IV). The patients were divided into 2 groups: a) those who had received intravenous Ambene intraoperatively (a study group) and 2) those who had undergone cytoreductive surgery without using hemostatic agents (a comparison group). Results. The Ambene-treated patients were observed to have a much lower volume of intraoperative blood loss than those who had no hemostatic therapy, which amounted to 80±12 and 550±11 ml, respectively. Conclusion. The findings are suggestive of the efficiency of single intraoperative administration of Ambene in patients with disseminated ovarian cancer after neoadjuvant chemotherapy.

Full Text

Restricted Access

About the authors

Yulia E. Dobrokhotova

N.I. Pirogov Russian National Research Medical University

Email: pr.dobrohotova@mail.ru
MD, Professor, Head of the Department of Obstetrics and Gynecology

Marina G. Venediktova

N.I. Pirogov Russian National Research Medical University

Email: marina.venediktova2012@yandex.ru
MD, Professor, Department of Obstetrics and Gynecology

Igor I. Grishin

N.I. Pirogov Russian National Research Medical University

Doctor of Medicine, Professor, Department of Obstetrics and Gynecology

Andrey N. Sarantsev

City Clinical Hospital 40, Moscow

PhD, associate professor, head of department of gynecological cancer

Ksenia V. Morozova

N.I. Pirogov Russian National Research Medical University

Email: morozovadk@mail.ru
PhD, assistant of obstetrics and gynecology

References

  1. Никогосян С.О., Кузнецов В.В. Современная диагностика рака яичников. Российский онкологический журнал. 2013; 5: 52-6. [Nikogosyan S.O., Kuznetsov V.V. Current diagnosis of ovarian cancer. Rossiyskiy onkologicheskiy zhurnal. 2013; 5: 52-6. (in Russian)]
  2. Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012; 1: 18-23. [Aksel E.M. Statistics of malignant neoplasms of female genital sphere. Onkoginekologiya. 2012; 1: 18-23. (in Russian)]
  3. Жорданиа К.И., Паяниди Ю.Г., Сонова М.М., Савостикова М.В., Баринов В.В., Калиничев Е.В. Эндометриоз и рак яичников. Онкогинекология. 2015; 2: 16-23. [Zhordania K.I., Payanidi Yu.G., Sonova M.M., Savostikova M.V., Barinov V.V., Kalinichev E.V. Endometriosis and ovarian cancer. Onkoginekologiya. 2015; 2: 16-23. (in Russian)]
  4. Важенин А.В., Жаров А.В., Шимоткина И.Г. Актуальные вопросы клинической онкогинекологии. М.; 2010. 128с. [Vazhenin A.V., Zharov A.V., Shimotkina I.G. Topical issues of clinical gynecological oncology. Moscow; 2010. 128p. (in Russian)]
  5. Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). М.: ФГУ «МНИОИ им. П.А Герцена Росмедтехнологий»; 2010. 256с. [Chissov V.I., Starinskiy V.V., Petrova G.V., eds. Malignancies in Russia in 2008 (morbidity and mortality). Moscow: FGU «MNIOI im. P.A. Gertsena Rosmedtehnologiy»; 2010. 256p. (in Russian)]
  6. Al-Safi Z.A., Edil B.H., Post M.D., Pearlman N.W., Alvero R. Fertility preservation in a patient with benign multicystic peritoneal mesothelioma. J. Surg. Oncol. 2014; 110(4): 372-4. doi: 10.1002/jso.23653.
  7. Переводчикова Н.И., Горбунова В.А., ред. Руководство по химиотерапии опухолевых заболеваний. М.: Практическая медицина; 2015. 688с. [Perevodchikova N.I., Gorbunova V.A., eds. Guide chemotherapy of tumor diseases. Moscow: Prakticheskaya meditsina; 2015. 688p. (in Russian)]
  8. Wang Y., Shwartz L.E., Anderson D., Lin M.T., Haley L., Wu R.C. et al. Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. Oncotarget. 2015; 6(26): 22949-58.
  9. Köbel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C. et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008; 5(12): e232. doi: 10.1371/journal.pmed.0050232.
  10. Loreto M.F., De Martinis M., Corsi M.P., Modesti M., Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol. Oncol. Res. 2000; 6(4): 301-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies